{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:52:56Z","timestamp":1773237176245,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T00:00:00Z","timestamp":1223856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Advanced hepatocellular carcinoma (HCC) patients who are not candidates for surgery or locoregional therapy are the focus of clinical trials of systemic therapy, as their overall prognosis remains poor. However, the current prognostic systems cannot reliably select appropriate candidates for systemic therapy trials based on the probability of 3\u2010month survival. In this study, the authors constructed a new prognostic score system, the Advanced Liver Cancer Prognostic System (ALCPS), which can objectively predict the probability of 3\u2010month survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Between 1990 and 2005, 1470 patients with advanced HCC who were not amendable to surgery or locoregional therapy were included in the analysis. The prognostic score system was developed from the multivariate Cox model through a point system and validated in an independent set. Okuda staging and Cancer of the Liver Italian Program (CLIP) score were also applied to the validation set to compare their predictive accuracy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>The ALCPS was based on 11 prognostic factors with different weights: ascites, abdominal pain, weight loss, Child\u2010Pugh grade, alkaline phosphatase, total bilirubin, alpha\u2010fetal protein, urea, portal vein thrombosis, tumor size, and presence of lung metastases. It stratified patients in both training and validation sets to different prognostic groups with significant difference in 3\u2010month overall survival (<jats:italic>P<\/jats:italic> &lt; .0001). By using the patients in the validation set with known 3\u2010month survival status, the ALCPS showed significantly better predictive power (area under the curve [AUC], 0.77) than Okuda score (AUC, 0.66; <jats:italic>P<\/jats:italic> &lt; .001) and CLIP score (AUC, 0.71; <jats:italic>P<\/jats:italic> = .002).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>The new prognostic system can objectively help the clinicians to select appropriate candidates for evaluation of treatment efficacy in systemic therapy trials for advanced HCC. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23878","type":"journal-article","created":{"date-parts":[[2008,10,13]],"date-time":"2008-10-13T19:54:14Z","timestamp":1223927654000},"page":"2742-2751","source":"Crossref","is-referenced-by-count":54,"title":["A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy"],"prefix":"10.1002","volume":"113","author":[{"given":"Thomas","family":"Yau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzy Jyun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheung Tat","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronnie T. P.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,11,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1440"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.696"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.9130"},{"key":"e_1_2_6_6_2","volume-title":"TMN Classification of Malignant Tumors","author":"Sobin H","year":"1997"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280322"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10384"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1007122"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.24563"},{"key":"e_1_2_6_13_2","volume-title":"Modelling Survival Data in Medical Research","author":"Collett D","year":"2003"},{"key":"e_1_2_6_14_2","unstructured":"SAS Institute Inc.SAS On line Documents. The PHREG Procedure: Variable Selection Methods."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/80.3.557"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1742"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00337.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.148.3.6878708"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901015)66:8<1685::AID-CNCR2820660805>3.0.CO;2-W"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-7-790"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji315"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23878","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:31:40Z","timestamp":1760275900000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23878"}},"subtitle":["Implication for patient selection in systemic therapy trials"],"short-title":[],"issued":{"date-parts":[[2008,11,3]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,11,15]]}},"alternative-id":["10.1002\/cncr.23878"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23878","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,3]]}}}